How 3D Bioprinted Wound-healing Patches Deliver Antibiotics and Better Outcomes for Diabetic Foot Ulcer Patients

Professor Dimitrios Lamprou, the chair of Biofabrication and Advanced Manufacturing at the School of Pharmacy, Queen’s University Belfast, who may have been destined to work on this novel 3D bioprinted wound-healing patch.

“We want to make treatment less painful and time-consuming for DFU patients with drug-loaded 3D bioprinted wound-healing scaffolds,” says Professor Dimitrios Lamprou of Queen’s University Belfast.

How a family member’s experience with diabetic foot ulcers inspired Prof. Lamprou’s 3D bioprinted wound-healing patch

The BIO X is helping accelerate the healing of diabetic foot ulcers (DFU) with 3D bioprinted patches that enable sustained release of antibiotics directly to the wound area. For the enterprising Lamprou Lab in Belfast, this breakthrough is more than academic; you could say it is also personal. 

It seems Professor Dimitrios Lamprou, the chair of Biofabrication and Advanced Manufacturing at the School of Pharmacy, Queen’s University Belfast, was destined for this project. He has always been an early adopter of emerging technologies, including 3D printers and bioprinters. In fact, over the past 4 years, his lab has worked on several 3D printed antibiotic scaffolds. But after seeing a family member undergo treatment for a DFU, it was a no-brainer that his next project would focus on improving the treatment of DFU wounds.  

3D bioprinted patches prevent bacterial infections that interfere with proper wound healing in diabetic foot ulcer patients

More than a third of diabetics develop DFUs in their lifetime, and nearly half of those wounds get infected, with Staphylococcus aureus, Pseudomonas and Escherichia coli being the most common pathogens. These infections contribute to poor wound-healing outcomes for diabetic patients and could even lead to lower-limb amputations. “I wanted to make DFU treatment less painful and time-consuming,” says the professor of pharmacy.  

Why extrusion-based 3D bioprinting and the BIO X were chosen to fabricate the biodegradable wound-healing patches

After experimenting with inkjet-based and laser-assisted biofabrication options, the team concluded that extrusion-based 3D bioprinting was the most promising technology in the context of DFU treatment. One distinct advantage with extrusion is the flexibility to use a wide range of biomaterials in one print. According to Professor Lamprou, thestraightforward” BIO X extrusion-based 3D bioprinter is also a game changer when it comes to setting printing parameters at the individual printhead level. He adds, “You could say the BIO X is foolproof because it is so easy to use. 

The FDA-approved polycaprolactone polymer proved to be the ideal biodegradable biomaterial for the wound-healing patch

The paper in Drug Delivery and Translational Research details how the BIO X bioprinted a mix of the biodegradable polymer polycaprolactone (PCL), which has been previously cleared by the FDA for use in other biomedical devices, with the broad-spectrum fluoroquinolone antibiotic levofloxacin to produce the wound-healing scaffolds. “These thermoplastic hydrogels are excellent for wound treatment given their biocompatibility, slow rate of degradation and good mechanical properties, such as flexibility to move freely,” explains Professor Lamprou.

At the patient level, Lamprou Lab’s antibiotic delivery patches solve several concerns. For example, the higher doses needed for oral administration of antibiotics can induce toxicity, while intravenous administration can be invasive, even requiring hospitalization. Not to mention reducing the proliferation of antibiotic-resistant bacterial strains attributed to the overuse of system-wide antibiotics. The slow degradation of PCL approach, however, facilitates the sustained, localized delivery of antibiotics at the wound site, provides a robust support structure as the skin repairs itself, and doctors can easily dress a wound in their office with no need for costly hospitalization.

CELLINK’s support team saved the day when the Belfast lab needed them most

Professor Lamprou is quick to add that CELLINK’s support team was invaluable. “The truly knowledgeable support team was there to answer our questions and offer practical suggestions, especially when it came to choosing polymers, making adjustments for different molecular weights and setting parameters. They saved us a lot of time,” the professor acknowledges. “To be honest, the level of service is unique. In one instance, when we had to send out our BIO X for maintenance, CELLINK went above and beyond by lending us the local sales office’s demo model to avoid delaying our experiments! You don’t hear of many companies doing this.”

Keep an eye out for more biomedical breakthroughs from the Lamprou Lab

“With modifications, our bioprinted drug-loaded scaffolds could potentially work for bone cancer, melanoma and also burns,” says Professor Lamprou. “So far, we have published only the results of the scaffolding and antibiotics. Once we have secured the relevant patents, we will publish more exciting discoveries related to incorporating additional biologics in the bioprinting to support the regrowth of tissue.” 

More Customer Spotlights

Innovative Silk Bioink for 3D Bioprinted Bone Marrow Tissue Models

There is a rising need of platelet units, which is primarily sourced from healthy donors. However, the natural production of platelets coupled with the brief shelf life does not meet the demand by the healthcare industry. Prof. Alessandra Balduini and her team at the University of Pavia are taking this challenge head-on by initiating the EIC Transition SILKink project, which aims to produce a groundbreaking platform that combines the use of natural silk and 3D bioprinting to recreate the environment of the human bone marrow where platelets are produced.

Bioprinting pediatric heart valves that stand the test of time

Heart valve disease is a significant global health issue, affecting millions of people and contributing to a substantial number of cardiovascular-related deaths. Traditional mechanical replacements, while life-saving, present several challenges, especially over time. Most mechanical valves do not grow or adapt with the patient’s body, leading to the need for multiple invasive surgeries. This not only poses inherent risks but also significantly impacts the patient’s quality of life. Issues such as blood clots, calcification, and severe inflammation further complicate the situation. These challenges become even more critical in pediatric cases, where conventional solutions, while still life-saving, may reduce life expectancy by up to 50%. Professor Savoji, Arman Jafari, a PhD student in his lab, and a dedicated team at the University of Montreal have employed bioprinting and their BIO X6 to address these challenges and develop a method to bioprint heart valve replacements.

Empowering Highly Motivated Researchers

We have interviewed Takaaki Arahira, the Associate Professor of the Department of Information Networks, Faculty of Management and Information Sciences at Kyushu Institute of Information Sciences.

Smart Biomaterials: Revolutionizing Drug Delivery

With so many disadvantages having the potential to severely undermine the successful outcome of the therapy, there is an immense requirement, driven by a fusion of both need and convenience, for biomaterials that operate autonomously and intelligently, effectively eliminating the need for human micromanagement. Professor Jeff Bates and his team at the University of Utah are taking this challenge head on. We spoke to Ashwin Velraj, PhD student in Professor Bates’ lab.